Q-omics provides the consensus-scored GALNT6 profile across patient tissues and cancer cell-line models. GALNT6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GALNT6 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, GALNT6 RNA expression shows 19,083 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where GALNT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT6 survival associations across molecular data types. GALNT6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT6 RNA expression–survival associations across cancer types. High GALNT6 expression shows unfavorable associations in BLCA, ACC, LGG, GBM and MESO, but favorable associations in OV. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for GALNT6 RNA expression.
This table summarizes GALNT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GALNT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT6 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, BLCA, COAD and LUAD. The HNSC box plot shows higher GALNT6 RNA expression in tumor versus normal tissue (log2 FC = +3.048, t-test p < 0.001).
This table shows molecular features associated with GALNT6 in patient tissues and cancer cell lines. In patient samples, GALNT6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
